Package Leaflet: Information for the User
Algidrin 600 mg Powder for Oral Suspension
Ibuprofen (Lysine)
Read all of this leaflet carefully before you start taking this medicine because it contains important information for you.
Contents of the Package Leaflet
Algidrin belongs to a group of medicines called analgesics. The active substance of this medicine, ibuprofen, is an analgesic, antipyretic, and non-steroidal anti-inflammatory drug that comes in the form of a soluble salt (Ibuprofen Lysine).
This medicine is used for the symptomatic treatment of pain, of mild to moderate intensity, and non-chronic inflammatory processes, such as headache, toothache, post-operative pain, musculoskeletal pain, and menstrual pain.
Do not take Algidrin if
Warnings and precautions
With ibuprofen, signs of allergic reaction to this medicine have been reported, such as respiratory problems, swelling of the face and neck area (angioedema), and chest pain. Stop using Algidrin immediately and contact your doctor or emergency services immediately if you notice any of these signs.
Consult your doctor or pharmacist before starting to take this medicine.
Gastrointestinal precautions
Precautions with other medicines
Cardiovascular and cerebrovascular precautions
Anti-inflammatory/analgesic medicines like ibuprofen may be associated with a small increased risk of heart attack or stroke, especially when used in high doses. Do not exceed the recommended dose or treatment duration.
You should discuss your treatment with your doctor or pharmacist before taking this medicine if:
Similarly, this type of medicine can cause fluid retention, especially in patients with heart failure and/or high blood pressure (hypertension).
Precautions during pregnancy and in women of childbearing age
Because the administration of ibuprofen has been associated with an increased risk of congenital anomalies/abortions, it is not recommended during the first and second trimester of pregnancy unless strictly necessary. In these cases, the dose and duration will be limited to the minimum possible.
In the third trimester, the administration of ibuprofeno is contraindicated.
For women of childbearing age, it should be taken into account that ibuprofen has been associated with a decrease in fertility.
Other disorders and considerations
If you have had kidney or liver disease.
If you have asthma or any other respiratory disorder.
In other conditions that predispose to fluid retention, ibuprofen should be administered with caution and under medical supervision. In elderly patients, in patients with blood disorders, tendency to bleeding, systemic lupus erythematosus (a chronic disease that affects the immune system and can affect various vital organs, the nervous system, blood vessels, skin, and joints), or mixed connective tissue disease, as it may cause aseptic meningitis (inflammation of the meninges that protect the brain and spinal cord, not caused by bacteria).
Skin Reactions
Severe skin reactions have been reported, such as exfoliative dermatitis, erythema multiforme, Stevens-Johnson syndrome, toxic epidermal necrolysis, drug reaction with eosinophilia and systemic symptoms (DRESS), and acute generalized exanthematous pustulosis (AGEP), in association with ibuprofen treatment. Discontinue treatment with this medicine and seek medical attention immediately if you notice any of the symptoms related to these severe skin reactions described in section 4.
Infections
Ibuprofen may hide the signs of an infection, such as fever and pain. Therefore, it is possible that ibuprofen may delay the appropriate treatment of the infection, which may increase the risk of complications. This has been observed in bacterial pneumonia and bacterial skin infections related to chickenpox. If you take this medicine while having an infection and the symptoms of the infection persist or worsen, consult a doctor without delay.
Other medicines and Algidrin
Tell your doctor or pharmacist if you are using, or have recently used, any other medicines, including those obtained without a prescription, especially furosemide, thiazide diuretics, digoxin, phenytoin, lithium, methotrexate, oral hypoglycemics, insulin, zidovudine, corticosteroids, bisphosphonates, or oxypentifylline. This medicine may affect or be affected by other medicines. For example:
Other medicines may also affect or be affected by treatment with this medicine. Therefore, you should always consult your doctor or pharmacist before using it with other medicines.
Taking Algidrin with food, drinks, and alcohol
This medicine can be taken independently of meals.
Consuming alcohol during treatment may increase the risk of adverse gastrointestinal reactions.
Pregnancy, breastfeeding, and fertility
Consult your doctor or pharmacist before using any medicine.
Do not take ibuprofen during the third trimester (see section precautions during pregnancy and in women of childbearing age).
It is recommended to avoid using this medicine during breastfeeding, as it passes into breast milk. If you are breastfeeding, consult your doctor.
Use in elderly patients
Generally, no dose adjustment is required, although in some cases a dose reduction may be necessary.
Use in children
This medicine is not recommended for children under 12 years of age due to the dose of active substance it contains.
Driving and using machines
Ibuprofen may cause, as a low-frequency adverse reaction, drowsiness or dizziness, which can interfere with the ability to drive or use machines.
Algidrin containscyclodextrin (betadex E-459), tartrazine (E-102),sucrose, and sodium.
-This medicine contains 3 g of cyclodextrin in each sachet.
-This medicine may cause allergic reactions because it contains tartrazine (E-102). It can cause asthma, especially in patients allergic to acetylsalicylic acid.
-This medicine contains sucrose. If your doctor has told you that you have an intolerance to certain sugars, consult with them before taking this medicine. It may cause cavities.
-This medicine contains less than 1 mmol (23 mg) per sachet, which is essentially "sodium-free".
Follow exactly the administration instructions of this medicine indicated by your doctor or pharmacist. In case of doubt, consult your doctor or pharmacist again.
The effective lowest dose should be used during the shortest necessary time to alleviate the symptoms. If you have an infection, consult a doctor without delay if the symptoms (such as fever and pain) persist or worsen (see section 2).
Adults
In adults and adolescents from 14 years of age, it is recommended to take one sachet (600 mg of ibuprofen) every 6-8 hours, according to the intensity of the symptoms and the evolution of the treatment.
Generally, the recommended daily dose is 1,200 mg of ibuprofen, divided into 3 or 4 doses. In some treatments, higher doses may be necessary, but in any case, it is recommended not to exceed the maximum daily dose of 2,400 mg of ibuprofen in adults and 1,600 mg in adolescents from 12 to 18 years of age.
Children:
This medicine is not recommended for children under 14 years of age, as the dose of ibuprofen it contains is not suitable for the recommended dosage in this group of patients.
Elderly patients:
It may be necessary for your doctor to prescribe a lower dose than usual. If so, the dose can only be increased once your doctor has checked that you tolerate the medicine well.
Patient with kidney and/or liver disease:
If you have kidney and/or liver disease, your doctor may prescribe a lower dose than usual. If so, take the exact dose that your doctor has prescribed.
Method of administration
For oral administration.
Pour the contents of one sachet into a half glass of water, stir, and take immediately.
Patient with stomach discomfort should take the medicine during meals.
Your doctor will indicate the duration of your treatment with this medicine. Do not stop treatment before the indicated time.
If you take more Algidrin than you should
If you have taken more medicine than you should, or if a child has accidentally taken the medicine, consult a doctor or pharmacist immediately, go to the nearest hospital, or call the Toxicology Information Service (telephone 91 562 04 20), indicating the medicine and the amount taken, to find out about the risk and ask for advice on the measures to take.
Symptoms of overdose may include nausea, stomach pain, vomiting (which may contain blood), headache, ringing in the ears, confusion, and involuntary eye movement. At high doses, symptoms of drowsiness, chest pain, palpitations, loss of consciousness, convulsions (mainly in children), weakness, and dizziness, blood in the urine, chills, and breathing problems have been reported.
In cases of ingestion of significant amounts, activated charcoal should be administered. Gastric lavage will be considered if significant amounts have been ingested and within 60 minutes after ingestion.
If you forget to take Algidrin
Do not take a double dose to make up for forgotten doses.
If you forget to take your corresponding dose, take it as soon as you remember. However, if the time for the next dose is near, skip the forgotten dose and take the next dose at the usual time.
If you have any other questions about the use of this medicine, ask your doctor or pharmacist.
Like all medications, this medication can have adverse effects, although not all people suffer from them.
The observed adverse effects are described below according to their frequency of presentation: very frequent (may affect more than 1 in 10 patients); frequent (may affect up to 1 in 10 patients); infrequent (may affect up to 1 in 100 patients); rare (may affect up to 1 in 1,000 patients); very rare (may affect up to 1 in 10,000 patients); frequency not known (cannot be estimated from the available data).
Gastrointestinal:
The most frequent adverse effects that may occur are gastrointestinal: nausea, vomiting, diarrhea, and dyspepsia. Infrequently, peptic ulcers, digestive hemorrhages, perforations (in some cases fatal), especially in elderly patients. Also, flatulence, constipation, heartburn, abdominal pain, gastritis, blood in stools, oral aphthae, worsening of ulcerative colitis, and Crohn's disease have been observed (frequency not known).
Cardiovascular:
It may be associated with a moderate increase in the risk of suffering a heart attack ("myocardial infarction") or stroke.
Rarely, edema (fluid retention), arterial hypertension, and heart failure (frequency not known) have been observed in association with treatments with this medication.
Frequency not known: Chest pain, which may be a symptom of a potentially severe allergic reaction called Kounis syndrome.
Cutaneous:
Immune system:
It may be associated, in very rare cases, with severe blistering reactions such as Stevens-Johnson syndrome (a clinical picture that affects the skin, mucous membranes, and other internal organs) and toxic epidermal necrolysis (a skin disease that manifests with the appearance of blisters and exfoliative lesions of the skin).
Rarely, hypersensitivity reactions (exaggerated reaction of the immune system) may be observed, which manifest as a skin rash with more or less itching, and anaphylactic reaction.
Very rarely, and in any case in predisposed patients, it may lead to bronchospasm (contraction of the bronchi).
Frequency not known: a severe skin reaction known as DRESS syndrome may occur. The symptoms of DRESS syndrome include: skin rash, inflammation of the lymph nodes, and elevated eosinophils (a type of white blood cell). Generalized red scaly rash, with bumps under the skin and blisters, mainly located in the skin folds, trunk, and upper limbs, accompanied by fever at the start of treatment (acute generalized exanthematous pustulosis). Stop taking Algidrin if you experience these symptoms and seek medical attention immediately. See also section 2. The skin becomes sensitive to light.
Central nervous system:
Rarely, a sensation of headache and somnolence may be observed. Neurological reactions such as depression, confusion, and dizziness.
Very rarely, aseptic meningitis (inflammation of the meninges not caused by bacteria) has been described.
Auditory:
Rarely, tinnitus may appear.
Ocular:
Very rarely, visual disturbances such as blurred vision, decreased visual acuity, or changes in color perception that remit spontaneously may be observed.
Blood:
Rarely, it may lead to hematological disorders such as thrombocytopenia (decrease in platelet count), agranulocytosis (decrease in neutrophil count, a type of white blood cell), aplastic anemia (decrease in red blood cells produced by a deficit in their formation), and hemolytic anemia (decrease in red blood cells produced by premature destruction).
Hepatic:
Ibuprofen may be associated, in rare cases, with liver damage.
If any of the following adverse effects occur, discontinue treatment and consult your doctor immediately:
Reporting of Adverse Effects
If you experience any type of adverse effect, consult your doctor, pharmacist, or nurse, even if it is a possible adverse effect that is not listed in this prospectus. You can also report them directly through the Spanish Pharmacovigilance System for Human Use Medicines: https://www.notificaram.es. By reporting adverse effects, you can contribute to providing more information on the safety of this medication.
It does not require special storage conditions.
Once the envelope is opened, the suspension should be prepared immediately according to the instructions for use.
Keep this medication out of the sight and reach of children.
Do not use this medication after the expiration date that appears on the packaging after (CAD). The expiration date is the last day of the month indicated.
Medications should not be thrown away through the sewers or in the trash. Deposit the packaging and medications that are no longer needed in the Sigre Point of the pharmacy. Ask your pharmacist how to dispose of the packaging and medications that are no longer needed. This way, you will help protect the environment.
Composition of Algidrin
Appearance of Algidrin and Package Contents
It is presented in the form of a white powder, packaged in envelopes.
Each package contains 20 single-dose envelopes.
Marketing Authorization Holder and Manufacturer
LABORATORIO DE APLICACIONES FARMACODINÁMICAS, S.A. (FARDI)
Grassot, 16; 08025 Barcelona (Spain)
Date of the Last Revision of this Prospectus:January 2024
Detailed information about this medication is available on the website of the Spanish Agency for Medicines and Health Products (AEMPS) http://www.aemps.gob.es/